The efficacy and safety of thymosin α1 for sepsis (TESTS): a multicentre, randomised, placebo-controlled phase 3 trial
In a 22-center, 1,106-patient phase 3 randomized controlled trial conducted in China, thymosin alpha-1 did not significantly reduce 28-day all-cause mortality in adults with sepsis compared with placebo (23.4% vs. 24.1%; hazard ratio 0.99). No secondary or safety outcome differed significantly between groups — a rigorously controlled result that tempers earlier, smaller studies suggesting benefit.
This is a summary. The reporting is The BMJ's, and the link below goes to the original article.